8-K: DBV Peanut Patch Phase 3 VITESSE Study Delivers Strong Data

DBV Technologies announced additional positive data from its Phase 3 VITESSE study for the VIASKIN Peanut Patch, showing significant desensitization in peanut-allergic children.

Summary

• Additional positive data from the successful Phase 3 VITESSE clinical trial for the VIASKIN Peanut Patch was presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting.
• The VITESSE study, the largest food allergy immunotherapy trial to date, assessed the VIASKIN Peanut Patch for treating peanut-allergic children aged 4 to 7 years.
• The study met its primary endpoint, with 46.6% of children in the VIASKIN Peanut arm meeting treatment responder criteria at 12 months, compared to 14.8% in the placebo arm, a statistically significant difference of 31.8% (95% CI: 24.5, 39.0%) that exceeded the prespecified 15% threshold.
• Approximately 82.8% of treated subjects increased their eliciting dose by at least one step at month 12, compared to 48% in the placebo group.
• Approximately 60.1% of treated subjects increased their eliciting dose by at least two steps at month 12, compared to 23.4% in the placebo group.
• Only 6.4% of treated subjects experienced a decrease in their eliciting dose, significantly lower than the 24% observed in the placebo group.
• The VIASKIN Peanut Patch was well tolerated, with the majority of treatment emergent adverse events being mild local application site reactions, consistent with previous Phase 3 studies.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, demonstrating strong efficacy and safety data for a key product candidate, which significantly de-risks the regulatory pathway and enhances the company's market position.

Positives

• The Phase 3 VITESSE study met its primary endpoint with a statistically significant treatment effect (p<0.001).
• 46.6% of children in the VIASKIN Peanut arm met responder criteria, significantly higher than 14.8% in the placebo arm, exceeding the lower bound prespecified threshold of 15%.
• 82.8% of treated subjects increased their eliciting dose by at least one step, compared to 48% in the placebo group, indicating successful desensitization.
• 60.1% of treated subjects increased their eliciting dose by at least two steps, compared to 23.4% in the placebo group, demonstrating a robust treatment effect.
• Only 6.4% of treated subjects saw a decrease in their eliciting dose, significantly better than the 24% in the placebo group who became more sensitized.
• All sensitivity analyses were statistically significant, confirming the robustness of the primary endpoint analysis.
• A significantly greater proportion of children treated with the VIASKIN Peanut Patch were responders in both baseline eliciting dose strata (ED < 30mg and ED >= 100mg).
• The VIASKIN Peanut Patch was well tolerated, with mostly mild local application site reactions, consistent with previous studies.
• The additional data suggest a broad and consistent treatment effect regardless of baseline eliciting dose strata or study population analysis.
• The data supports a Biologics License Application (BLA) submission to the FDA, which is planned for the first half of this year.

Risks

• Uncertainties are associated generally with research and development, clinical trials, and related regulatory reviews and approvals.
• DBV's product candidates have not yet been authorized for sale in any country.
• There are uncertainties regarding DBV's ability to successfully execute on its budget discipline measures.
• Actual results could differ materially from forward-looking statements and estimates due to various factors.

Future Outlook

The company plans to submit a Biologics License Application (BLA) to the FDA in the first half of this year, leveraging the positive VITESSE study data. If approved, the VIASKIN Peanut Patch aims to provide a non-invasive treatment option for peanut-allergic children, offering a convenient solution for caregivers.

Management Comments

• "The additional data presented at this year's AAAAI Annual Meeting suggest a broad and consistent treatment effect of the VIASKIN Peanut Patch, regardless of baseline eliciting dose strata or study population analysis." David Fleischer M.D., Global Principal Investigator of the VITESSE study.
• "The increases in eliciting dose seen are clinically meaningful and may reflect a reduced risk of an allergic reaction. Conversely, nearly four times as many children on placebo saw their eliciting dose decrease, becoming more sensitized over the twelve-month period." David Fleischer M.D.
• "These results not only support the VIASKIN Peanut Patch as a potential treatment option for peanut-allergic children, if approved, but also reinforce the importance of prioritizing a proactive treatment for this specific patient population." David Fleischer M.D.
• "We believe the additional data presented today demonstrate that the VIASKIN Peanut Patch consistently induced desensitization among subjects irrespective of study subgroup or baseline characteristics." Pharis Mohideen M.D., Chief Medical Officer of DBV Technologies.
• "If approved, the VIASKIN Peanut Patch would provide caregivers with a non-invasive option that fits into daily activities. To that end, these data support a Biologics License Application, which we are planning to submit to FDA in the first half of this year." Pharis Mohideen M.D.

Industry Context

StockSavvy.ai notes that the successful Phase 3 VITESSE study results position DBV Technologies favorably in the growing market for food allergy treatments, particularly for pediatric peanut allergy. The non-invasive nature of the VIASKIN Peanut Patch could offer a significant advantage over oral immunotherapies, potentially improving patient adherence and caregiver convenience. This advancement could challenge existing or developing treatments by offering a differentiated delivery method.

Comparison to Industry Standards

• The VITESSE study is noted as the 'largest food allergy immunotherapy trial to date,' indicating a significant scale compared to previous studies in the field.
• The 31.8% difference in response rates between treatment and placebo arms (46.6% vs. 14.8%) is a strong efficacy signal, which can be benchmarked against other approved or late-stage therapies for food allergies, such as Palforzia (oral immunotherapy for peanut allergy), which showed a responder rate of 67.2% vs. 13.6% placebo in its pivotal trial (PALISADE), though responder definitions and patient populations may differ.
• The high percentage of treated subjects increasing their eliciting dose (82.8% by one step, 60.1% by two steps) indicates a robust desensitization effect, which is a key measure of success in allergy immunotherapy trials.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, increased likelihood of regulatory approval, and potential for future revenue generation.
• Patients (peanut-allergic children aged 4-7): Potential for a new, non-invasive treatment option to reduce the risk of allergic reactions and improve quality of life.
• Caregivers: Potential for a convenient, non-invasive treatment that fits into daily activities.
• Regulatory Authorities (FDA): The data supports a BLA submission, indicating progress towards a potential new approved therapy.

Next Steps

• Submission of a Biologics License Application (BLA) to the FDA in the first half of this year.
• Ongoing clinical trials of the VIASKIN Peanut Patch in peanut allergic toddlers (1 through 3 years of age).

Key Dates

Recommendation

The filing presents overwhelmingly positive Phase 3 clinical trial data for the VIASKIN Peanut Patch, a significant de-risking event for DBV Technologies. The statistically significant efficacy, strong responder rates, and favorable safety profile, coupled with the clear intent to file a BLA in the first half of the year, indicate a high probability of regulatory approval. This product addresses a substantial unmet medical need in a non-invasive manner, positioning the company for significant market penetration and future revenue growth. Investors should view this as a strong catalyst for the stock.

Keywords

Peanut allergy, VIASKIN Peanut Patch, EPIT, Phase 3, VITESSE study, AAAAI, Biologics License Application, FDA, Desensitization, Food allergy, Immunotherapy, DBV Technologies